NCT06222372 (INDIGO#2) is a NA clinical trial of Rifampin in Leprosy, sponsored by Annemieke Geluk.

Who is sponsoring NCT06222372?

NCT06222372 is sponsored by Annemieke Geluk.

What drugs are being tested in NCT06222372?

Interventions in NCT06222372: Rifampin.

Is NCT06222372 still recruiting?

NCT06222372 is currently recruiting now. Last updated 10 September 2025.

Last reviewed 2025-09-10 · How we verify

NCT06222372: INDIGO#2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Interventions and Diagnostic Tests for Leprosy

Recruiting now NA Last updated 10 September 2025

What this trial tests

NA trial testing Rifampin in Leprosy in 1,100 participants. Currently enrolling.

Timeline

4 March 2020

Primary endpoint
1 June 2026

15 December 2026

Quick facts

Lead sponsor	Annemieke Geluk
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	1,100
Start date	4 March 2020
Primary completion	1 June 2026
Estimated completion	15 December 2026
Sites	1 location across Bangladesh

Drugs / interventions tested

Rifampin — full drug profile →

Conditions studied

Leprosy — all drugs for Leprosy →

Sponsor

Annemieke Geluk

Who can join

5 and older, any sex, with Leprosy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Contact with Mycobacterium leprae (M. leprae) infected individuals is a risk factor for development of leprosy. Thus, detection of asymtomatically M. leprae infected individuals, allowing informed decision making on who needs treatment at a preclinical stage, is vital to interrupt transmission and can help prevent leprosy. In a previous field trial the BCG vaccine was applied alone and combined with a single dose of rifampin (SDR) as prophylactic interventions in contacts of leprosy patients in Bangladesh. Concurrently, blood-derived host immune-profiles specific for M. leprae infection or leprosy disease were assessed in the same population by merging detection of innate, adaptive cellular as well as humoral immunity. This has led to the identification of selected host-immune markers, currently applied in a low complexity lateral flow assay based on up-coverting particles (UCP-LFA), providing a convenient tool to assess M. leprae infection, allowing assessment of efficacy of prophylactic interventions in a point-of-care setting. The proposed study aims to determine the effect of post-exposure prophylaxis by SDR on M. leprae infection rate using UCP-LFA before and after prophylaxis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rapid test for Mycobacterium leprae infection: a practical tool for leprosy.
Pierneef L, van Hooij A, de Jong D, Wassenaar G, et al · · 2024 · cited 10× · PMID 39617937 · DOI 10.1186/s40249-024-01262-9
Large-scale field application of a fingerstick blood test for Mycobacterium leprae infection: Monitoring population-wide effects of case finding and post-exposure prophylaxis on transmission in the Comoros and Madagascar.
Pierneef L, Braet SM, de Jong D, Ramboarina S, et al · · 2025 · cited 1× · PMID 41329688 · DOI 10.1371/journal.pgph.0005270

Verify or expand the search:

Other trials of Rifampin

Trials testing the same drug.

NCT07357610 — An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healt · Phase 1 · recruiting
NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm · Phase 1 · completed
NCT06701136 — Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults · Phase 1 · not yet recruiting
NCT06917495 — Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis · Phase 2 · not yet recruiting

Other recruiting trials for Leprosy

Currently open trials in the same condition.

NCT07515989 — Accuracy of the Polymerase Chain Reaction of Ulnar Perineural Subcutaneous Aspirate Guided by Ultrasound for the Diagnos · NA · recruiting
NCT06761469 — Leprosy Active Searching Trial in Brazil · NA · recruiting
NCT06819449 — Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients · NA · recruiting
NCT06683690 — TGF β 1 Expression Related Gene Polymorphism · recruiting
NCT05597280 — Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06222372 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Annemieke Geluk
Last refreshed: 10 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06222372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing